0 CHECKOUT

Nasopharyngeal Cancer - Pipeline Review, H1 2015

  • ID: 3099769
  • January 2015
  • 87 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Ambrx, Inc.
  • BioDiem Ltd
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • MORE

Nasopharyngeal Cancer - Pipeline Review, H1 2015

Summary

This, ‘Nasopharyngeal Cancer - Pipeline Review, H1 2015’, provides an overview of the Nasopharyngeal Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nasopharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ambrx, Inc.
  • BioDiem Ltd
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Nasopharyngeal Cancer Overview
Therapeutics Development
Pipeline Products for Nasopharyngeal Cancer – Overview
Pipeline Products for Nasopharyngeal Cancer – Comparative Analysis
Nasopharyngeal Cancer – Therapeutics under Development by Companies
Nasopharyngeal Cancer – Therapeutics under Investigation by Universities/Institutes
Nasopharyngeal Cancer – Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Nasopharyngeal Cancer – Products under Development by Companies
Nasopharyngeal Cancer – Products under Investigation by Universities/Institutes
Nasopharyngeal Cancer – Companies Involved in Therapeutics Development
Ambrx, Inc.
AVEO Pharmaceuticals, Inc.
BioDiem Ltd
Celgene Corporation
Cyclacel Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Merck & Co., Inc.
Otsuka Holdings Co., Ltd.
Pharmacyclics, Inc.
Theravectys S.A.
Zhejiang BetaPharma Co., Ltd.
Nasopharyngeal Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abexinostat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
azacitidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Metastatic Nasopharyngeal Carcinoma and Colorectal Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Nasopharingeal Carcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target Latent Membrane Protein-2 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target LMP-1 and LMP-2 for Metastatic Nasopharyngeal Carcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target LMP-1 and LMP-2 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cells + Cytokine Induced Killer Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EBV-nRNA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ficlatuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate p53 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2849330 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
icotinib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-2206 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Drug Conjugate to Inhibit CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NEO-212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPB-51602 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RO-5203280 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
seliciclib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Nasopharyngeal and Colon Cancers - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for EBV Associated Nasopharyngeal Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Epstein-Barr Viral Infections and Nasopharyngeal Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine to Target EBV for Nasopharyngeal Carcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nasopharyngeal Cancer – Recent Pipeline Updates
Nasopharyngeal Cancer - Dormant Projects
Nasopharyngeal Cancer – Product Development Milestones
Featured News & Press Releases
Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer
May 29, 2009: Cyclacel Reports Initial Phase 2 Seliciclib Data In Patients With Nasopharyngeal Carcinoma At 2009 Asco Annual Meeting
Apr 21, 2009: Cyclacel & Dartmouth Researchers Reports Novel Mechanism Of Action For Seliciclib At AACR
Mar 05, 2009: Cyclacel Announces Phase 1 Data Elucidating Pharmacodynamics & Mechanism Of Action Of Seliciclib In Nasopharyngeal Cancer
Aug 28, 2008: CYCLACEL Announces Recommendations Of Data Review Committee For Seliciclib Phase 2b Non-Small Cell Lung Cancer APPRAISE Trial
Jun 28, 2007: Cyclacel Pharmaceuticals Announces Results Of Phase II Seliciclib Combination Studies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Nasopharyngeal Cancer, H1 2015
Number of Products under Development for Nasopharyngeal Cancer – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Nasopharyngeal Cancer – Pipeline by Ambrx, Inc., H1 2015
Nasopharyngeal Cancer – Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Nasopharyngeal Cancer – Pipeline by BioDiem Ltd, H1 2015
Nasopharyngeal Cancer – Pipeline by Celgene Corporation, H1 2015
Nasopharyngeal Cancer – Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015
Nasopharyngeal Cancer – Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Nasopharyngeal Cancer – Pipeline by GlaxoSmithKline plc, H1 2015
Nasopharyngeal Cancer – Pipeline by Merck & Co., Inc., H1 2015
Nasopharyngeal Cancer – Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Nasopharyngeal Cancer – Pipeline by Pharmacyclics, Inc., H1 2015
Nasopharyngeal Cancer – Pipeline by Theravectys S.A., H1 2015
Nasopharyngeal Cancer – Pipeline by Zhejiang BetaPharma Co., Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Nasopharyngeal Cancer Therapeutics – Recent Pipeline Updates, H1 2015
Nasopharyngeal Cancer – Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Nasopharyngeal Cancer, H1 2015
Number of Products under Development for Nasopharyngeal Cancer – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Ambrx, Inc.
AVEO Pharmaceuticals, Inc.
BioDiem Ltd
Celgene Corporation
Cyclacel Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Merck & Co., Inc.
Otsuka Holdings Co., Ltd.
Pharmacyclics, Inc.
Theravectys S.A.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)